Overexpression of E-cadherin and β-catenin proteins in metastatic prostate cancer cells in bone

Prostate

Volumn 68, Issue 1, 2008, Pages 78-84

  Saha, Baisakhi ^a   Arase, Ahren ^a   Imam, Sarah S ^a   Tsao Wei, Denice ^b   Naritoku, Wesley Y ^b   Groshen, Susan ^b   Jones, Lawrence W ^a   Imam, S Ashraf ^a  

^a HUNTINGTON MEDICAL RESEARCH INSTITUTES   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

catenin; Bone metastasis; E cadherin; Immunohistochemical staining; Prostate cancer

Indexed keywords

BETA CATENIN; UVOMORULIN;

ARTICLE; BONE METASTASIS; CANCER CELL; CANCER CLASSIFICATION; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; FISHER EXACT TEST; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; MALE; PRIMARY TUMOR; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROTEIN EXPRESSION;

BETA CATENIN; BIOPSY; BONE NEOPLASMS; CADHERINS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS;

EID: 37449009461     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20670     Document Type: Article

References (22)

1. Hirohashi S. Inactivation of the E-cadherin-mediated cell adhesion system in human cancers. Am J Pathol 1998;153:333-339.
2. Kemler R. From cadherins to catenins: Cytoplasmic protein interactions and regulation of cell adhesion. Trends Genet 1993;9:317-321.
3. Ozawa M, Kemler R. The membrane-proximal region of the E-cadherin cytoplasmic domain prevents dimerization and negatively regulates adhesion activity. J Cell Biol 1998;142:1605-1613.
4. Cavallaro U, Christofori G. Multitasking in tumor progression: Signaling functions of cell adhesion molecules. Ann NY Acad Sci 2004;1014:58-66.
5. Lipponen P, Saarelainen E, Ji H, Aaltomaa S, Syrjanen K. Expression of E-Cadherin (E-CD) as related to other prognostic factors and survival in breast cancer. J Pathol 1994;174:101-109.
6. Guildford P, Hopkins J, Harraway J, McLeod M, McLeod N, Harawira P, Taite N, Scoutar R, Miller A, Reeve AE. E-Cadherin germline mutations in familial gastric cancer. Nature 1998;392:402-405.
7. Umbas R, Isaacs WB, Bringuier PP, Schaafsma HE, Karthaus HFM, Ooosterhof GON, Debruyne FMJ, Schalken JA. Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res 1994;54:3929-3933.
8. Imam SA, Esteban EF, Chen RS, Cardiff RD, Taylor CR. Identification of a cell-surface antigen (LEA.135) associated with favorable prognosis in human breast cancer. Cancer Res 1993;53:3233-3236.
9. Schipper JH, Frixen UH, Behrens J, Unger A, Jahnke K, Birchmeier W. E-cadherin expression in squamous cell carcinomas of head and neck: Inverse correlation with tumor differentiation and lymph node metastasis. Cancer Res 1991;51:6328-6337.
10. Mehta CR, Patel NR. A network Algorithm for performing Fisher's exact test in rXc contingency tables. J Am Stat Assoc 1983;78:427-434.
11. Wang J, Krill D, Torbenson M, Wang Q, Bisceglia M, Stoner J, Thomas A, DeFlavia P, Dhir R, Becich MJ. Expression of cadherins and catenins in paired tumor and non-neoplastic primary prostate cultures and corresponding prostatectomy specimens. Urol Res 2000;28:308-315.
12. Kallakury BV, Sheehan CE, Winn-Deen E, Oliver J, Fisher HA, Kaufman RP Jr, Ross JS. Decreased expression of catenins (alpha and beta), p120 CTN, and E-cadherin cell adhesion proteins and E-cadherin gene promoter methylation in prostatic adenocarcinomas. Cancer 2001;92:27886-27895.
13. Jaggi M, Johansson SL, Baker JJ, Smith LM, Galich A, Balaji KC. Aberrant expression of E-cadherin and β-catenin in human prostate cancer. Urol Oncol 2005;23:402-406.
14. Mareel M, Bracke M, Van Roy F. Cancer metastasis: Negative regulation by an invasion-suppressor complex. Cancer Detect Prev 1995;19:451-464.
15. Bryden AA, Hoyland JA, Freemont AJ, Clarke NW, Schembri WD, George NJ. E-cadherin and beta-catenin are downregulated in prostate bone metastases. Br J Urol Int 2002;89:400-403.
16. Wiltshire RN, Duray P, Bittner ML, Visakorpi T, Meltzer PS, Tuthill RJ, Liotta LA, Trent JM. Direct visualization of the clonal progression of primary cutaneous melanoma: Application of tissue microdissection and comparative genomic hybridization. Cancer Res 1995;55:3954-3957.
17. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, Van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347:1999-2009.
18. Ramaswamy S, Ross KN, Lander ES, Golub TR. A molecular signature of metastasis in primary solid tumors. Nat Genet 2003;33:49-54.
19. Graff JR, Herman JG, Lapidus RG, Chopra H, Xu R, Jariard DF, Isaacs WB, Pitha PM, Davidson NE, Baylin SB. E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res 1995;55:5195-5199.
20. Hurtubise A, Mompalar RL. Evaluation of antineoplastic action of 5-aza-2′-deoxycytidine (Dacogen) and docetaxel (Taxotere) on human breast, lung and prostate carcinoma cell lines. Anticancer Drugs 2004;15:161-167.
21. Berx G, Van Roy F. The E-cadherin/catenin complex: An important gatekeeper in breast cancer tumorigenesis and malignant progression. Breast Cancer Res 2001;3:289-293.
22. Berx G, Staes K, van Hengel J, Molemans F, Bussemakers MJG, van Bokhoven A, van Roy F. Cloning and characterization of the human invasion suppressor gene E-Cadherin (CDH1). Genomics 1995;26:218-289.